Given that hyper-excitability, interneuron dysfunctions, and network abnormalities are features often associated with, and could precede full clinical onset of, AD [111], APP and sAPPα are therefore potentially useful in countering MCI and certain aspects of AD pathology, as demonstrated recently in a mouse AD model [52]. The gene discussed is APP; the disease is Alzheimer disease.